PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+10.64%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.37B
AUM Growth
+$2.37B
(-9.4%)
Cap. Flow
-$299M
Cap. Flow
% of AUM
-12.64%
Top 10 Holdings %
Top 10 Hldgs %
36.09%
Holding
95
New
14
Increased
16
Reduced
24
Closed
14
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$30.4M |
| 2 |
Agilent Technologies
A
|
$27.5M |
| 3 |
Elevance Health
ELV
|
$21.2M |
| 4 |
Arcellx
ACLX
|
$19.1M |
| 5 |
Universal Health Services
UHS
|
$17.5M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$83.4M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$76.2M |
| 3 |
Axsome Therapeutics
AXSM
|
$43.7M |
| 4 |
Veeva Systems
VEEV
|
$33.4M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
$26.3M |
Sector Composition
| 1 | Healthcare | 95.68% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
AstraZeneca
AZN
$248B
| $39.1M | 1.4% | 576,800 | – | – |
|
|
27
Elevance Health
ELV
$71.8B
| $34.4M | 1.23% | 67,115 +41,315 | +160% | +$21.2M |
|
28
Thermo Fisher Scientific
TMO
$186B
| $34.2M | 1.23% | 62,143 | – | – |
|
29
Avantor
AVTR
$9.18B
| $33.9M | 1.21% | 1,607,612 -472,045 | -23% | -$9.96M |
|
|
PNT
30
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $33.8M | 1.21% | 4,633,802 +118,586 | +3% | +$864K |
|
31
Waters Corp
WAT
$18B
| $32.4M | 1.16% | 94,624 -23,010 | -20% | -$7.88M |
|
|
32
BioMarin Pharmaceuticals
BMRN
$11.2B
| $32.1M | 1.15% | 310,401 -805,548 | -72% | -$83.4M |
|
|
33
Intuitive Surgical
ISRG
$170B
| $30.4M | 1.09% | +114,450 | New | +$30.4M |
|
34
Caribou Biosciences
CRBU
$174M
| $28M | 1% | 4,459,783 -1,540,217 | -26% | -$9.67M |
|
|
35
Agilent Technologies
A
$35.7B
| $27.5M | 0.98% | +183,504 | New | +$27.5M |
|
|
KRTX
36
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $25.6M | 0.92% | 130,293 | – | – |
|
37
BioCryst Pharmaceuticals
BCRX
$1.74B
| $24.8M | 0.89% | 2,162,411 | – | – |
|
|
SGEN
38
DELISTED
Seagen Inc. Common Stock
SGEN
| $24.7M | 0.89% | 192,384 -172,831 | -47% | -$22.2M |
|
39
Johnson & Johnson
JNJ
$427B
| $24.3M | 0.87% | 137,746 | – | – |
|
40
HCA Healthcare
HCA
$94.5B
| $22.1M | 0.79% | 91,945 -83,290 | -48% | -$20M |
|
41
Procept Biorobotics
PRCT
$2.23B
| $21.5M | 0.77% | 517,526 | – | – |
|
42
Erasca
ERAS
$445M
| $20.7M | 0.74% | 4,797,460 -2,467,521 | -34% | -$10.6M |
|
|
ISEE
43
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $19.6M | 0.7% | 917,557 +661,273 | +258% | +$14.2M |
|
|
44
Arcellx
ACLX
$3.85B
| $19.1M | 0.68% | +616,515 | New | +$19.1M |
|
|
45
Universal Health Services
UHS
$11.6B
| $17.5M | 0.63% | +124,421 | New | +$17.5M |
|
46
Apellis Pharmaceuticals
APLS
$3.48B
| $16.5M | 0.59% | 318,422 +196,542 | +161% | +$10.2M |
|
47
Icon
ICLR
$13.8B
| $15.9M | 0.57% | 81,725 -53,015 | -39% | -$10.3M |
|
48
Charles River Laboratories
CRL
$8.04B
| $15.9M | 0.57% | +72,820 | New | +$15.9M |
|
49
DexCom
DXCM
$29.5B
| $15.3M | 0.55% | +135,465 | New | +$15.3M |
|
50
Editas Medicine
EDIT
$231M
| $13M | 0.47% | 1,466,732 +187,678 | +15% | +$1.66M |
|